title: Molecular and cellular bases of chronic myeloid leukemia.
abstract: Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the overproduction of granulocytes, which leads to high white blood cell counts and splenomegaly in patients. Based on clinical symptoms and laboratory findings, CML is classified into three clinical phases, often starting with a chronic phase, progressing to an accelerated phase and ultimately ending in a terminal phase called blast crisis. Blast crisis phase of CML is clinically similar to an acute leukemia; in particular, B-cell acute lymphoblastic leukemia (B-ALL) is a severe form of acute leukemia in blast crisis, and there is no effective therapy for it yet. CML is induced by the BCR-ABL oncogene, whose gene product is a BCR-ABL tyrosine kinase. Currently, inhibition of BCR-ABL kinase activity by its kinase inhibitor such as imatinib mesylate (Gleevec) is a major therapeutic strategy for CML. However, the inability of BCR-ABL kinase inhibitors to completely kill leukemia stem cells (LSCs) indicates that these kinase inhibitors are unlikely to cure CML. In addition, drug resistance due to the development of BCRABL mutations occurs before and during treatment of CML with kinase inhibitors. A critical issue to resolve this problem is to fully understand the biology of LSCs, and to identify key genes that play significant roles in survival and self-renewal of LSCs. In this review, we will focus on LSCs in CML by summarizing and discussing available experimental results, including the original studies from our own laboratory.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
authors.forename: Yaoyu
authors.initials: Y
authors.lastname: Chen
authors.forename: Cong
authors.initials: C
authors.lastname: Peng
authors.forename: Dongguang
authors.initials: D
authors.lastname: Li
authors.forename: Shaoguang
authors.initials: S
authors.lastname: Li
mesh_terms: D058927:5-Lipoxygenase-Activating Proteins / Q000378:metabolism; D000818:Animals; D001549:Benzamides; D004195:Disease Models, Animal; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000473:pathology*; D008297:Male; D051379:Mice; D014411:Neoplastic Stem Cells / Q000201:enzymology* / Q000473:pathology*; D051059:PTEN Phosphohydrolase / Q000378:metabolism; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use; D017354:Point Mutation; D017434:Protein Structure, Tertiary; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D058927:5-Lipoxygenase-Activating Proteins; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D051059:PTEN Phosphohydrolase